A somatic point mutation in the tyrosine kinase JAK2 (V617F) is detected in most patients with polycythenia vera (PV) and in approximately half of those with essential thrombocythemia (ET), as well as in other myeloid disorders such as de novo acute myeloid leukemia (AML; B6%), myelodysplastic syndrome (MDS; B4%), chronic myelomonocytic leukemia (CMML; B20%) and atypical myeloproliferative disease (MPD). In contrast, JAK2 V617F was not detected in the patients with acute or chronic lymphoid malignancies. 1 In these studies, most of these mutations were heterozygous mutation and homozygous mutation was only detected in 30% of patients with JAK2 mutation using DNA samples. 2 Thus, the prevalence of the expression of JAK2 V617F in myeloid malignancies remains unclear.
In the present study, we examined the expression of JAK2 V617F in 241 Japanese patients with myeloid malignancies. The morphologic subtypes of AML and MDS were initially classified according to the French-American-British (FAB) criteria. A diagnosis of transformation from MDS to AML (MDS-AML) was made when the bone marrow (BM) consisted of more than 30% blasts. Leukemic cells from BM were collected after informed consent was obtained. Mononuclear cells were isolated using the Ficoll-Hypaque density gradient centrifugation method, followed by total cellular RNA extraction. Expression of the JAK2 gene was determined by reverse transcription-PCR, as described previously.
3 Mutation analysis of V617F was then performed by direct sequencing of these PCR products.
A homozygous JAK2 V617F mutation was detected in the HEL cell line, which was established from a patient with erythroleukemia (AML M6 as defined by the FAB classification) and in which the JAK2/STAT5 signal transduction pathway is constitutively activated. 4 Among de novo AML, only heterozygous JAK2 V617F mutation was detected in the patients with AML M6 (1 of 53 patients; 2%) and AML M7 (2 of 11 cases; 18%). 5, 6 None of the 198 patients with de novo AML tested showed expression of JAK2 V617F, including nine cases with M6 and eight cases with M7 (Table 1 ). These observations suggest that the prevalence of the expression of JAK2 V617F in de novo AML appears to be less frequent than the reported detection rate of the genetic mutation using DNA samples.
In contrast to de novo AML, expression of the JAK2 V617F mutation was found in 2 of 18 cases (11%) of MDS-AML but not Table 1 Prevalence of the expression of JAK2 V617F in myeloid malignancies Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome.
Letters to the Editor in eight cases with refractory anemia (RA) or 17 cases with refractory anemia with excess blasts (RAEB) ( Table 1 ). In both cases with the mutation, most of fluorescent intensity at codon 617 was V617F and the wild type was only faintly visible, suggesting that most of the leukemic cells expressed V617F. A previous study found a high occurrence of the JAK2 V617F mutation in RA with ringed sideroblasts associated with marked thrombocytosis (71%), 7 and this mutation has also been detected in MDS with myelofibrosis (33%). 8 In our two cases with the mutation, neither thrombocytosis nor myelofibrosis was detected (Table 2) . Interestingly, the blastic cells of these two cases were small with pale agranular cytoplasms and cytoplasmic blebs, and expressed CD41 antigen, suggesting that blastic cells have a megakaryoblastic nature. The progenitor cells of MDS are believed to undergo a multistep process during transformation into overt acute myelogenous leukemia. Several genetic abnormalities have been detected in both MDS and MSD-AML patients, which have suggested that genetic alterations are closely associated with disease progression of MDS. 3 Therefore, MDS serves as a useful model for studying the abnormal genetic events that occur in leukemogenesis. We detected expression of JAK2 V617F in MDS-AML but not in RA or RAEB, suggesting that expression of JAK2 V617F may be one of the genetic factors involved in the progression of MDS to AML with a megakaryoblastic nature.
In conclusion, detection of the expression of the JAK2 gene mutation in MDS-AML patients may enhance both the management of these patients and the application of adequate therapeutic strategies such as tyrosine kinase inhibitors. 
